Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene

Priya Maseelall, Jared C. Robins, Daniel B. Williams, Michael A. Thomas*

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Objective: To report a case of a pelvic desmoid tumor that was treated with the antiestrogen toremifene after a failed attempt at surgical excision. Design: Case report. Setting: University reproductive endocrine practice. Patient(s): A reproductive-aged woman with a recurrent desmoid tumor. Intervention(s): After surgical excision of a desmoid tumor that presented during childbirth, subsequent recurrence resulted in the use of toremifene for tumor stabilization. Main Outcome Measure(s): Magnetic resonance imaging was used to monitor desmoid tumor size. Result(s): One year after postsurgical recurrence of the desmoid tumor, the patient began treatment with the antiestrogen toremifene. Tumor stabilization and regression with symptomatic relief was observed. Nine years of antiestrogen use revealed no progression in tumor size or patient symptoms. After the patient demonstrated perimenopausal symptoms, toremifene administration was discontinued without a return of symptoms or tumor growth after 3 years. Conclusion(s): Our case demonstrates that toremifene is a safe and effective therapy that can be used for the stabilization and regression of desmoid tumors. An antiestrogen should be considered as adjuvant therapy after surgery and as a first-line treatment with disease recurrence. Discontinuation of antiestrogen therapy was shown to be done safely after the patient started to show signs of decreased endogenous estrogen production.

Original languageEnglish (US)
Pages (from-to)509.e11-509.e13
JournalFertility and Sterility
Volume84
Issue number2
DOIs
StatePublished - Aug 2005

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene'. Together they form a unique fingerprint.

  • Cite this